Mortality risk among hemodialysis patients receiving different vitamin D analogs

This publication has 43 references indexed in Scilit:

• Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study
  Kidney International, 2006
• Inhibition of Parathyroid Hormone: A Dose Equivalency Study of Paricalcitol and Doxercalciferol
  American Journal of Nephrology, 2005
• Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study
  Kidney International, 2005
• Disruption of Nuclear Vitamin D Receptor Gene Causes Enhanced Thrombogenicity in Mice
  Journal of Biological Chemistry, 2004
• Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
  Nephrology Dialysis Transplantation, 2004
• Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
  Kidney International, 2003
• Calcitriol Therapy Modulates the Cellular Immune Responses in Hemodialysis Patients
  American Journal of Nephrology, 2000
• Calcitriol Directly Sensitizes Renal Tubular Cells to ATP-Depletion- and Iron-Mediated Attack
  The American Journal of Pathology, 1999
• Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia
  American Journal of Kidney Diseases, 1996
• Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
  Journal of Clinical Investigation, 1984